Compare · ALMR vs BIO
ALMR vs BIO
Side-by-side comparison of Alamar Biosciences Inc. (ALMR) and Bio-Rad Laboratories Inc. (BIO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ALMR and BIO operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- BIO is the larger of the two at $9.87B, about 5.3x ALMR ($1.87B).
- ALMR has been more active in the news (19 items in the past 4 weeks vs 3 for BIO).
- BIO has more recent analyst coverage (12 ratings vs 5 for ALMR).
- Company
- Alamar Biosciences Inc.
- Bio-Rad Laboratories Inc.
- Price
- -
- -
- Market cap
- $1.87B
- $9.87B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2026
- 1980
- News (4w)
- 19
- 3
- Recent ratings
- 5
- 12
Bio-Rad Laboratories Inc.
Bio-Rad Laboratories, Inc. develops, manufactures, and markets life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. It operates in two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cell biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, transfusion laboratories, and insurance and forensic testing laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
Latest ALMR
- Large owner Qiming Corporate Gp Vi, Ltd. sold $3,327,146 worth of shares (111,313 units at $29.89) (SEC Form 4)
- Alamar Biosciences to Participate in Upcoming Investor Conferences
- SEC Form 10-Q filed by Alamar Biosciences Inc.
- Large owner Qiming Corporate Gp Vi, Ltd. sold $5,676,413 worth of shares (187,636 units at $30.25) (SEC Form 4)
- Alamar Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Financial Statements and Exhibits
- Alamar Biosciences Reports Third Quarter 2026 Financial Results and Raises 2026 Revenue Guidance
- Alamar Biosciences Partners with GSK on Large-Scale Proteomic Study to Advance Precision Medicine
- UPDATE -- Alamar Biosciences and Nightingale Health to Lead UK Biobank 80,000-Sample Neurodegenerative Disease Study
- Alamar Biosciences and Nightingale Health to Lead UK Biobank 80,000-Sample Neurodegenerative Disease Study
- Large owner Qiming Corporate Gp Vi, Ltd. sold $5,968,888 worth of shares (185,731 units at $32.14) (SEC Form 4)
Latest BIO
- Bio-Rad Reports Third-Quarter 2026 Financial Results
- Bio-Rad to Participate in Fireside Chat During UBS Global Healthcare Conference
- Bio-Rad to Report Third-Quarter 2026 Financial Results on Wednesday, November 4, 2026
- Bio-Rad to Participate in Fireside Chat During Bernstein Insights Healthcare Leaders and Disruptors 3rd Annual Forum
- Bio-Rad to Participate in Fireside Chat During Wells Fargo’s 21st Annual Healthcare Conference
- IMDX Reports Second Quarter 2026 Results and Timely Progress on FDA Review of GraftAssureDx
- Bio-Rad Reports Second-Quarter 2026 Financial Results
- Bio-Rad to Report Second-Quarter 2026 Financial Results on Tuesday, August 4, 2026
- RBC Capital Mkts resumed coverage on Bio-Rad Labs with a new price target
- Bio-Rad to Participate in Upcoming Investor Conferences